{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04910685",
            "orgStudyIdInfo": {
                "id": "BLU-263-1201"
            },
            "organization": {
                "fullName": "Blueprint Medicines Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis",
            "therapeuticArea": [
                "Rare Diseases",
                "Other"
            ],
            "study": "harbor-study-to-evaluate-efficacy-and-safety-of-blu-versus-placebo-in-patients-with-indolent-systemic-mastocytosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-11-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-17",
            "studyFirstSubmitQcDate": "2021-05-27",
            "studyFirstPostDateStruct": {
                "date": "2021-06-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Blueprint Medicines Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. Parts 1 and 2 will enroll patients with ISM. Patients enrolled in Part 1 or Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part M will enroll patients with monoclonal mast cell activation syndrome (mMCAS). Part S will enroll participants with smoldering systemic mastocytosis (SSM). The study also includes PK groups that will enroll patients with ISM."
        },
        "conditionsModule": {
            "conditions": [
                "Indolent Systemic Mastocytosis",
                "Monoclonal Mast Cell Activation Syndrome",
                "Smoldering Systemic Mastocytosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "In Part 1 of the study, participants with ISM will be randomly assigned to 1 of 3 doses of elenestinib + BSC or to placebo + BSC. Once the recommended dose (RD) of elenestinib is identified in Part 1, participants with ISM in Part 2 will be randomly assigned to receive elenestinib at the RD + BSC or matching placebo + BSC. Participants will be randomized 2:1 to elenestinib:placebo. In Part 3, participants who have completed treatment in Part 1 or Part 2 of the study (including those initially randomized to placebo) will participate in a long-term open-label extension, receiving elenestinib at the RD + BSC. In Part M of the study, participants with monoclonal mast cell activation syndrome will receive elenestinib + BSC at the RD in an open-label fashion. In Part S of the study, participants with smoldering systemic mastocytosis (SSM) will receive open-label elenestinib + BSC. The study also includes PK groups that will enroll patients with ISM",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 463,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "(Part 1) Elenestinib Dose 1 + BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive best supportive care (BSC) and Dose 1 of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily until completion of Part 1.",
                    "interventionNames": [
                        "Drug: Elenestinib"
                    ]
                },
                {
                    "label": "(Part 1) Elenestinib Dose 2 + BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive BSC and Dose 2 of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily until completion of Part 1.",
                    "interventionNames": [
                        "Drug: Elenestinib"
                    ]
                },
                {
                    "label": "(Part 1) Elenestinib Dose 3 + BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive BSC and Dose 3 of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily until completion of Part 1.",
                    "interventionNames": [
                        "Drug: Elenestinib"
                    ]
                },
                {
                    "label": "(Part 1) Placebo + BSC",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Patients will receive BSC and matching placebo. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily until completion of Part 1",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "(Part 2) Elenestinib RD + BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive BSC and the recommended dose (RD) of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily for approximately 24 weeks",
                    "interventionNames": [
                        "Drug: Elenestinib"
                    ]
                },
                {
                    "label": "(Part 2) Placebo + BSC",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Patients will receive BSC and matching placebo. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily once daily for approximately 24 weeks",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "(Part 3) Elenestinib RD + BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive open-label BSC and the RD of elenestinib for up to approximately 4 years.",
                    "interventionNames": [
                        "Drug: Elenestinib"
                    ]
                },
                {
                    "label": "(Part M) Elenestinib RD + BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive BSC and the RD of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily for the duration of participation in the study.",
                    "interventionNames": [
                        "Drug: Elenestinib"
                    ]
                },
                {
                    "label": "PK Groups (Dose 2 or Dose 3)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive BSC and Dose 2 or Dose 3 of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally for the duration of participation in the study.",
                    "interventionNames": [
                        "Drug: Elenestinib"
                    ]
                },
                {
                    "label": "(Part S) Elenestinib + BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with Smoldering Systemic Mastocytosis (SSM) will receive open-label BSC and elenestinib for up to approximately 4 years.",
                    "interventionNames": [
                        "Drug: Elenestinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Elenestinib",
                    "description": "Elenestinib oral tablet",
                    "armGroupLabels": [
                        "(Part 1) Elenestinib Dose 1 + BSC",
                        "(Part 1) Elenestinib Dose 2 + BSC",
                        "(Part 1) Elenestinib Dose 3 + BSC",
                        "(Part 2) Elenestinib RD + BSC",
                        "(Part 3) Elenestinib RD + BSC",
                        "(Part M) Elenestinib RD + BSC",
                        "(Part S) Elenestinib + BSC",
                        "PK Groups (Dose 2 or Dose 3)"
                    ],
                    "otherNames": [
                        "BLU-263"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo oral tablet",
                    "armGroupLabels": [
                        "(Part 1) Placebo + BSC",
                        "(Part 2) Placebo + BSC"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Parts 1 and 3: Number of participants with Adverse Events (AEs)",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "Part 2: Objective Response Rate (ORR), defined as proportion of patients who achieve \u226530% reduction from baseline in ISM-Symptom in Assessment Form (ISM-SAF) Total Symptom Score (TSS)",
                    "timeFrame": "Baseline, Week 25"
                },
                {
                    "measure": "Parts 1 and 3: Mean change from baseline in ISM-SAF TSS",
                    "description": "The ISM-SAF has a scale of 0-110. A decrease in score corresponds to improvement in symptoms",
                    "timeFrame": "Baseline up to 4 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Parts 1, 2, and 3: Mean change from baseline in measures of mast cell burden",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Parts 1, 2, and 3: Mean change from baseline in ISM-SAF individual symptom scores",
                    "description": "Each symptom in the ISM-SAF has a scale of 0-10. A decrease in score corresponds to improvement in symptoms",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Parts 1, 2, and 3: Time to achieve 30% reduction from baseline in ISM-SAF scores",
                    "description": "Time to achieve a 30% reduction in scores generated by the ISM-SAF. The ISM-SAF uses a score from 0-110 and a lower score represents lower symptom burden",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Part 2: Proportion of patients with a \u226550% reduction from baseline in serum tryptase",
                    "timeFrame": "Baseline, Week 25"
                },
                {
                    "measure": "Part 2: Proportion of patients who achieve at least a 50% reduction in peripheral blood KIT D816V allele fraction, or a reduction to undetectable levels",
                    "timeFrame": "Baseline, Week 25"
                },
                {
                    "measure": "Part 2: Mean change from baseline in ISM-SAF",
                    "description": "The ISM-SAF has a scale of 0-110. A decrease in score corresponds to improvement in symptoms",
                    "timeFrame": "Baseline, Week 25"
                },
                {
                    "measure": "Part 2: Proportion of patients with a \u226550% reduction in bone marrow mast cells or reduction to no aggregates for patients with aggregates at Baseline",
                    "timeFrame": "Baseline, Week 25"
                },
                {
                    "measure": "Part 2: ORR",
                    "timeFrame": "Week 25"
                },
                {
                    "measure": "Parts 2 and 3: Change form baseline in number of concomitant BSC medications",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Parts 2 and 3: Change from baseline in ISM-SAF leading symptom score",
                    "description": "Each symptom in the ISM-SAF has a scale of 0-10. A decrease in score corresponds to improvement in symptoms",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Parts 2 and 3: Mean change from baseline in Quality of Life scores",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Part 2: Number of participants with AEs",
                    "timeFrame": "Up to Week 25"
                },
                {
                    "measure": "Part S: Number of participants with AEs",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Part S: Proportion of participants who achieve a Complete Remission (CR)/Complete remission with partial recovery of peripheral blood counts (CRh), molecular CR/molecular CRh, or Partial Response (PR) based on Pure Pathologic Response (PPR) from Baseline",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Part S: Mean change in ISM-SAF from Baseline to after 24 weeks of treatment",
                    "timeFrame": "Week 25"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\nAll Patients\n\n-1. Patient must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.\n\nPart 1 and Part 2\n\n* 2. Patient must have moderate-to-severe symptoms based on minimum mean total symptom score (TSS) of the ISM Symptom Assessment Form (ISM-SAF) over the 14-day eligibility screening period.\n* 3. Patient has confirmed diagnosis of ISM, confirmed by Central Pathology Review of BM biopsy and central review of B- and C-findings by WHO diagnostic criteria. Archival biopsy may be used if completed within the past 12 months.\n* 4. Patient must have failed to achieve adequate symptom control for 1 or more Baseline symptoms, as determined by the Investigator, with at least 2 of the following symptomatic therapies administered: H1 blockers, H2 blockers, proton-pump inhibitors, leukotriene inhibitors, cromolyn sodium, corticosteroids, or omalizumab.\n* 5. Patients must have BSC for ISM symptom management stabilized for at least 14 days prior to starting screening procedures.\n* 6. For patients receiving corticosteroids, the dose must be \u2264 20 mg/d prednisone or equivalent, and the dose must be stable for \u2265 14 days.\n\nPart M\n\n* 7. Patients must have mMCAS, confirmed by Central Pathology Review of BM biopsy. An archival biopsy may be used if completed within the past 12 months.\n* 8. Patients must have tryptase \\< 20 ng/mL.\n* 9. Patients must have KIT D816V in peripheral blood (PB) or BM and/or CD25+ Mast cells in BM.\n* 10. Patients must have symptoms consistent with mast cell activation (despite BSC) in at least two organ systems characterized by cutaneous flushing, tachycardia, syncope, hypotension, diarrhea, nausea, vomiting and gastro-intestinal cramping) and serum blood tryptase (sBT) levels above 8 ng/mL OR Severe (Ring and Messmer grading \u2265 II, recurrent anaphylaxis, including but not limited to hymenoptera venom, drug or food, regardless of sBT levels.\n\nPK Groups\n\n* 11. See inclusion criteria for All patients and Part 1/Part 2\n* 12. Accrual may be limited to patients who have specific disease manifestations (ie, GI involvement) or are taking acid-reducing agents to better explore the impact of these features on PK.\n\nPart S:\n\n-13. Patient has confirmed diagnosis of SSM, confirmed by Central Pathology Review of BM biopsy and central review of B- and C-findings by WHO 2022 diagnostic criteria.\n\nKey Exclusion Criteria:\n\n* 1. Patient has been diagnosed with any of the following WHO systemic mastocytosis (SM) sub-classifications: cutaneous mastocytosis only, SM with an associated hematologic neoplasm of non-MC lineage (SM-AHN), aggressive SM, mast cell leukemia, or mast cell sarcoma.\n* 2. Patient has been diagnosed with another myeloproliferative disorder.\n* 3. Patient has organ damage C-findings attributable to SM.\n* 4. Patient has clinically significant, uncontrolled, cardiovascular disease\n* 5. Patient has a QT interval corrected using Fridericia's formula (QTcF) \\> 480 msec.\n* 6. Patient has previously received treatment with any targeted KIT inhibitors.\n* 7. Patient has a history of a primary malignancy that has been diagnosed or required therapy within 3 years. The following prior malignancies are not exclusionary: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site.\n* 8. Time since any cytoreductive therapy including mastinib and midostaurin should be at least 5 half-lives or 14 days (whichever is longer), and for cladribine, interferon alpha, pegylated interferon, or antibody therapy \\< 28 days or 5 half-lives of the drug (whichever is longer), before beginning the screening period.\n* 9.Patient has received radiotherapy or psoralen and ultraviolet A (PUVA) therapy \\< 14 days before beginning the screening period.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "16 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Blueprint Medicines",
                    "role": "CONTACT",
                    "phone": "617-714-6707",
                    "email": "medinfo@blueprintmedicines.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Stanford Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                },
                {
                    "facility": "Brigham and Women's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Michigan Medicine University of Michigan",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Mayo Clinic",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55902",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Roswell Park Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Columbia University Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of Cincinnati Medical Center",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "The University of Texas, MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute, University of Utah",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Princess Alexandra Hospital",
                    "status": "RECRUITING",
                    "city": "Woolloongabba",
                    "state": "Queensland",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.48855,
                        "lon": 153.03655
                    }
                },
                {
                    "facility": "The Alfred Hospital",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3004",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Kepler Universitatsklinikum, Med Campus III. Clinic of Internal Medicine 3 - Hematology and Oncology",
                    "status": "RECRUITING",
                    "city": "Linz",
                    "zip": "4021",
                    "country": "Austria",
                    "geoPoint": {
                        "lat": 48.30639,
                        "lon": 14.28611
                    }
                },
                {
                    "facility": "Unitversitair Ziekenhuis Antwerpen",
                    "status": "RECRUITING",
                    "city": "Edegem",
                    "state": "Antwerpen",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.15662,
                        "lon": 4.44504
                    }
                },
                {
                    "facility": "CHU Amiens-Picardie",
                    "status": "RECRUITING",
                    "city": "Amiens",
                    "zip": "80000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 49.9,
                        "lon": 2.3
                    }
                },
                {
                    "facility": "CHU de Caen",
                    "status": "RECRUITING",
                    "city": "Caen",
                    "country": "France",
                    "geoPoint": {
                        "lat": 49.18585,
                        "lon": -0.35912
                    }
                },
                {
                    "facility": "CHU Grenoble",
                    "status": "RECRUITING",
                    "city": "Grenoble Cedex 9",
                    "zip": "38043",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.16667,
                        "lon": 5.71667
                    }
                },
                {
                    "facility": "CHU de Limoges",
                    "status": "RECRUITING",
                    "city": "Limoges Cedex",
                    "zip": "87042",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.83153,
                        "lon": 1.25781
                    }
                },
                {
                    "facility": "CHU de Nantes",
                    "status": "RECRUITING",
                    "city": "Nantes",
                    "zip": "44093",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.21725,
                        "lon": -1.55336
                    }
                },
                {
                    "facility": "H\u00f4pital de la Piti\u00e9 Salp\u00e9tri\u00e8re",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75013",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "H\u00f4pital Necker - D\u00e9partementd 'H\u00e9matologieA dultes",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75015",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "CHU de Poitiers",
                    "status": "RECRUITING",
                    "city": "Poitiers",
                    "zip": "86000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 46.58333,
                        "lon": 0.33333
                    }
                },
                {
                    "facility": "CHU Toulouse - Hopital Larrey",
                    "status": "RECRUITING",
                    "city": "Toulouse",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.60426,
                        "lon": 1.44367
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum RWTH Aachen Klinik f\u00fcr H\u00e4matologie, Onkologie, H\u00e4mostaseologie und Stammzelltransplantation",
                    "status": "RECRUITING",
                    "city": "Aachen",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.77664,
                        "lon": 6.08342
                    }
                },
                {
                    "facility": "Charit\u00e9 - Universit\u00e4tsmedizin Berlin Institute of Allergology",
                    "status": "RECRUITING",
                    "city": "Berlin",
                    "zip": "12203",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 52.52437,
                        "lon": 13.41053
                    }
                },
                {
                    "facility": "University Clinic Erlangen",
                    "status": "RECRUITING",
                    "city": "Erlangen",
                    "zip": "91054",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.59099,
                        "lon": 11.00783
                    }
                },
                {
                    "facility": "University Clinic Hamburg Eppendorf",
                    "status": "RECRUITING",
                    "city": "Hamburg",
                    "zip": "20246",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 53.57532,
                        "lon": 10.01534
                    }
                },
                {
                    "facility": "Universit\u00e4tsmedizin Mannheim III. Medizinische Klinik Universit\u00e4t Heidelberg Medizinische Fakult\u00e4t Mannheim",
                    "status": "RECRUITING",
                    "city": "Mannheim",
                    "zip": "68167",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.4891,
                        "lon": 8.46694
                    }
                },
                {
                    "facility": "LMU Klinikum",
                    "status": "RECRUITING",
                    "city": "Munich",
                    "zip": "80377",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 48.13743,
                        "lon": 11.57549
                    }
                },
                {
                    "facility": "Dipartimentod i Oncoematologia Istituto Scientifico Romagnolop er lo studio e la cura dei tumori (IRST)- IRCCS",
                    "status": "RECRUITING",
                    "city": "Meldola",
                    "state": "Forli-Cesena",
                    "zip": "47014",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.12775,
                        "lon": 12.0626
                    }
                },
                {
                    "facility": "UOC Ematologia",
                    "status": "RECRUITING",
                    "city": "Milano",
                    "state": "Lombardia",
                    "zip": "20122",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "SOD Ematologia (Ambulatori)- AOUC Azienda Ospedaliero Universitaria Careggi",
                    "status": "RECRUITING",
                    "city": "Firenze",
                    "state": "Toscana",
                    "zip": "50134",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 43.77925,
                        "lon": 11.24626
                    }
                },
                {
                    "facility": "Unita Operativa di Ematologia AOU Policlinico S. Orsola-Malpighi",
                    "status": "RECRUITING",
                    "city": "Bologna",
                    "zip": "40138",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.49381,
                        "lon": 11.33875
                    }
                },
                {
                    "facility": "S.C. Ematologia Fondazione I.R.C.C.S. Policlinico San Matteo",
                    "status": "RECRUITING",
                    "city": "Pavia",
                    "zip": "27100",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.19205,
                        "lon": 9.15917
                    }
                },
                {
                    "facility": "S.S.D. Immunologia Clinica e Allergologia Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona",
                    "status": "RECRUITING",
                    "city": "Salerno",
                    "zip": "84131",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 40.67545,
                        "lon": 14.79328
                    }
                },
                {
                    "facility": "Unit\u00e0 Operativa di Allergologia Azienda Ospedaliera Universitaria Integrata di Verona",
                    "status": "RECRUITING",
                    "city": "Verona",
                    "zip": "37126",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.4299,
                        "lon": 10.98444
                    }
                },
                {
                    "facility": "ErasmusMC",
                    "status": "RECRUITING",
                    "city": "Rotterdam",
                    "state": "Zuid-Holland",
                    "zip": "3015 GD",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 51.9225,
                        "lon": 4.47917
                    }
                },
                {
                    "facility": "University Medical Center Groningen",
                    "status": "RECRUITING",
                    "city": "Groningen",
                    "zip": "9713 GZ",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 53.21917,
                        "lon": 6.56667
                    }
                },
                {
                    "facility": "Oslo University Hospital",
                    "status": "RECRUITING",
                    "city": "Oslo",
                    "zip": "N-0424",
                    "country": "Norway",
                    "geoPoint": {
                        "lat": 59.91273,
                        "lon": 10.74609
                    }
                },
                {
                    "facility": "Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo Antonio dos Capuchos",
                    "status": "RECRUITING",
                    "city": "Lisbon",
                    "zip": "1169-050",
                    "country": "Portugal",
                    "geoPoint": {
                        "lat": 38.71667,
                        "lon": -9.13333
                    }
                },
                {
                    "facility": "CHUPorto, EPE - Hospital de Santo Ant\u00f3nio",
                    "status": "RECRUITING",
                    "city": "Porto",
                    "zip": "4099-001",
                    "country": "Portugal",
                    "geoPoint": {
                        "lat": 41.14961,
                        "lon": -8.61099
                    }
                },
                {
                    "facility": "Centro Hospitalar Universitario Sao Joao, E.P.E.",
                    "status": "RECRUITING",
                    "city": "Porto",
                    "zip": "4200-139",
                    "country": "Portugal",
                    "geoPoint": {
                        "lat": 41.14961,
                        "lon": -8.61099
                    }
                },
                {
                    "facility": "Hospital Universitario Vall d'Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario Ramon y Cajal",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28034",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Virgen del Valle - Instituto de Estudios de Mastocitosis de Castilla-La Mancha",
                    "status": "RECRUITING",
                    "city": "Toledo",
                    "zip": "45071",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.8581,
                        "lon": -4.02263
                    }
                },
                {
                    "facility": "University Hospital Basel",
                    "status": "RECRUITING",
                    "city": "Basel",
                    "zip": "C-4031",
                    "country": "Switzerland",
                    "geoPoint": {
                        "lat": 47.55839,
                        "lon": 7.57327
                    }
                },
                {
                    "facility": "Luzerner Kantonsspital",
                    "status": "RECRUITING",
                    "city": "Luzern",
                    "zip": "6000",
                    "country": "Switzerland",
                    "geoPoint": {
                        "lat": 47.05048,
                        "lon": 8.30635
                    }
                },
                {
                    "facility": "University Hospital of Wales",
                    "status": "RECRUITING",
                    "city": "Cardiff",
                    "state": "Wales",
                    "zip": "CF14 4XW",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.48,
                        "lon": -3.18
                    }
                },
                {
                    "facility": "Cancer and Haematology Centre",
                    "status": "RECRUITING",
                    "city": "Oxford",
                    "zip": "OX3 7LE",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.75222,
                        "lon": -1.25596
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008415",
                    "term": "Mastocytosis"
                },
                {
                    "id": "D000034721",
                    "term": "Mastocytosis, Systemic"
                },
                {
                    "id": "D000090267",
                    "term": "Mast Cell Activation Syndrome"
                },
                {
                    "id": "D000090362",
                    "term": "Mast Cell Activation Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009372",
                    "term": "Neoplasms, Connective Tissue"
                },
                {
                    "id": "D000018204",
                    "term": "Neoplasms, Connective and Soft Tissue"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M11399",
                    "name": "Mastocytosis",
                    "asFound": "Mastocytosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M24449",
                    "name": "Mastocytosis, Systemic",
                    "asFound": "Indolent Systemic Mastocytosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2769",
                    "name": "Mast Cell Activation Syndrome",
                    "asFound": "Mast Cell Activation Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2776",
                    "name": "Mast Cell Activation Disorders",
                    "asFound": "Monoclonal Mast Cell Activation Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12317",
                    "name": "Neoplasms, Connective Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M20350",
                    "name": "Neoplasms, Connective and Soft Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3626",
                    "name": "Mastocytosis",
                    "asFound": "Mastocytosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5562",
                    "name": "Systemic Mastocytosis",
                    "asFound": "Systemic Mastocytosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3624",
                    "name": "Mast Cell Activation Syndrome",
                    "asFound": "Mast Cell Activation Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3868",
                    "name": "Monoclonal Mast Cell Activation Syndrome",
                    "asFound": "Monoclonal Mast Cell Activation Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}